首页> 美国卫生研究院文献>International Journal of Molecular Sciences >Fibrinogen as a Pleiotropic Protein Causing Human Diseases: The Mutational Burden of Aα Bβ and γ Chains
【2h】

Fibrinogen as a Pleiotropic Protein Causing Human Diseases: The Mutational Burden of Aα Bβ and γ Chains

机译:纤维蛋白原作为导致人类疾病的多亲蛋白:AαBβ和γ链的突变负担

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fibrinogen is a highly pleiotropic protein that is involved in the final step of the coagulation cascade, wound healing, inflammation, and angiogenesis. Heterozygous mutations in Aα, Bβ, or γ fibrinogen-chain genes (FGA, FGB, FGG) have been described as being responsible for fibrinogen deficiencies (hypofibrinogenemia, hypo-dysfibrinogenemia, dysfibrinogenemia) and for more rare conditions, such as fibrinogen storage disease and hereditary renal amyloidosis. Instead, biallelic mutations have been associated with afibrinogenemia/severe hypofibrinogenemia, i.e., the severest forms of fibrinogen deficiency, affecting approximately 1–2 cases per million people. However, the “true” prevalence for these conditions on a global scale is currently not available. Here, we defined the mutational burden of the FGA, FGB, and FGG genes, and estimated the prevalence of inherited fibrinogen disorders through a systematic analysis of exome/genome data from ~140,000 individuals belonging to the genome Aggregation Database. Our analysis showed that the world-wide prevalence for recessively-inherited fibrinogen deficiencies could be 10-fold higher than that reported so far (prevalence rates vary from 1 in 106 in East Asians to 24.5 in 106 in non-Finnish Europeans). The global prevalence for autosomal-dominant fibrinogen disorders was estimated to be ~11 in 1000 individuals, with heterozygous carriers present at a frequency varying from 3 every 1000 individuals in Finns, to 1–2 every 100 individuals among non-Finnish Europeans and Africans/African Americans. Our analysis also allowed for the identification of recurrent (i.e., FGG-p.Ala108Gly, FGG-Thr47Ile) or ethnic-specific mutations (e.g., FGB-p.Gly103Arg in Admixed Americans, FGG-p.Ser245Phe in Africans/African Americans).
机译:纤维蛋白原是高度多效性蛋白,参与凝血级联,伤口愈合,炎症和血管生成的最终步骤。 Aα,Bβ或γ纤维蛋白原链基因(FGA,FGB,FGG)的杂合突变已被描述为造成纤维蛋白原缺乏症(低纤维蛋白原血症,低纤维蛋白原异常血症,血纤维蛋白原异常)和更罕见的疾病,例如纤维蛋白原贮积病和遗传性肾淀粉样变性。相反,双等位基因突变与纤维蛋白原血症/严重的低纤维蛋白原血症相关,即最严重的纤维蛋白原缺乏症,每百万人中约有1-2例。但是,目前尚无法获得全球范围内这些条件的“真实”流行率。在这里,我们定义了FGA,FGB和FGG基因的突变负担,并通过对属于基因组聚合数据库的〜140,000个人的外显子组/基因组数据进行系统分析,估计了遗传纤维蛋白原疾病的患病率。我们的分析表明,全世界隐性遗传性纤维蛋白原缺乏症的患病率可能是迄今为止报道的10倍(东亚地区的患病率从10 6 中的1到10 <2非芬兰人的sup> 6 )。据估计,常染色体显性纤维蛋白原疾病的全球患病率约为1000人中的11人,杂合子携带者的发生频率从芬兰人每千人中有3人到非芬兰欧洲人和非洲人中每100人中有1-2人不等。非洲裔美国人。我们的分析还可以确定复发性(即FGG-p.Ala108Gly,FGG-Thr47Ile)或种族特异性突变(例如,混血美国人中的FGB-p.Gly103Arg,非洲人/非裔美国人的FGG-p.Ser245Phe)。 。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号